Risk for Ocular Hypertension With Intravitreal Dexamethasone Implants in Black and White Patients With Diabetic Macular Edema
Overview
Authors
Affiliations
To compare the effects of intravitreal (IVT) 0.7 mg dexamethasone implants on the intraocular pressure (IOP) in Black patients and White patients with diabetic macular edema (DME). A retrospective cohort study was performed of Black patients and White patients with DME who received dexamethasone implants with 12 or more months of follow-up. The study included 145 eyes (69 Black; 76 White) with a mean (±SD) of 3.6 ± 3.9 dexamethasone implants and 58 31 months of follow-up. Black patients had higher baseline rates of glaucoma (23% vs 8%; = .010) but similar rates of ocular hypertension after receiving IVT dexamethasone (20% vs 16%; = .52). By the last follow-up visit, the mean central subfield thickness had decreased from 387 129 µm to 314 104 µm ( < .001). IVT dexamethasone implants decreased macular thicknesses in patients with DME; however, there was no difference in the rate of ocular hypertension after IVT dexamethasone between Black patients and White patients.